ASCO GU 2021: Outcomes of first-line immunotherapy combinations in metastatic kidney cancer

Combinations of immunotherapy drugs nivolumab plus ipilimumab and immunotherapy/vascular endothelial growth factor (VEGF) inhibitors are widely used for the treatment of metastatic renal cell carcinoma (RCC). However, limited information is available to compare the outcomes from different combinations. At the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) over the weekend, data […]

read more

ASCO GU 2021: Combinations of lenvatinib plus pembrolizumab or everolimus improved survival in untreated patients with advanced kidney cancer

Results from the phase 3 CLEAR study, presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium over the weekend, showed that lenvatinib used in combination with either pembrolizumab or everolimus resulted in improved survival and tumour shrinkage compared to sunitinib when used as a first-line treatment for patients with advanced renal cell […]

read more

ASCO GU 2021: Comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for advanced papillary kidney cancer

A gene called MET codes for a protein called MET tyrosine protein kinase (also called hepatocyte growth factor receptor), which  stimulates the growth and development of tumours. MET tyrosine protein kinase is a key driver of the growth and development of papillary renal cell carcinoma (pRCC). In this study presented at the American Society of […]

read more

ASCO GU 2021: Combination of HIF-2α inhibitor and cabozantinib is active in previously treated advanced kidney cancer

In a small phase 2 study presented at the virtual American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), the novel hypoxia-inducible factor 2α (HIF-2α) inhibitor, belzutifan (MK-6482), showed promising anti-cancer activity in combination with cabozantinib in patients with metastatic clear cell renal cell carcinoma (RCC) that had been previously treated. Kidney cancers develop […]

read more

ASCO GU 2021: Immunotherapy for untreated non-clear cell kidney cancer

Results of a retrospective study presented during the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) looked at the effect of immune checkpoint inhibitors (immunotherapy, e.g. nivolumab, ipilimumab, pembrolizumab) on the survival of patients with metastatic non-clear cell renal cell carcinoma (RCC) compared to targeted therapy with vascular endothelial growth factor (VEGF) […]

read more

ASCO GU 2021: Long-term follow-up of kidney cancer patients on nivolumab plus ipilimumab combination

Long-term follow-up data from the CheckMate-214 study of the nivolumab plus ipilimumab combination in untreated, advanced clear cell kidney cancer patients were presented at the virtual American Society for Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) in San Francisco this weekend. Patients were followed for at least 4 years after treatment with nivolumab plus ipilimumab […]

read more
Showing 1 to 6 of 1051 results
  TOP